One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Modern Imaging in Prostate Cancer: Do We Treat Patients, or Their Scans?
Malcolm D.MasonaTheodorus H.van der KwastbNicolasMottetcDaniela E.Oprea-LagerdOlivierRouvièreefEAU-EANM-ESTRO-ESUR-ISUP-SIOG Prostate Cancer Guidelines Panelâ€
Combination of Tadalafil and Finasteride for the Treatment of Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Commercialization of the Prescribing Cascade
David-DanNguyenaQuoc-DienTrinhbNaeemBhojanic
Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer
KosjYamoahaShivanshuAwasthiaBrandon A.MahaljShuang G.ZhaokG. DanielGrassaAndersBerglundaJulietaAbraham-MirandaaTravisGerkeaRobert J.RounbehleraElaiDavicionidYangLiudJongParkaJohn L.ClevelandaJulio M.Pow-SangaDanielFernandezaJavierTorres-RocaaR. JeffreyKarneseEdwardSchaefferf…FelixFengi
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma
J. AlbertoNakauma-Gonzálezabc†MaudRijndersc†Jobvan RietabcMichiel S.van der HeijdendJensVoortmaneEdwinCuppenfgNivenMehrahSandravan WilpehSjoukje F.OostingiL. LuciaRijstenbergjHans M.WestgeestkEllen C.ZwarthoffjRonaldde WitcAstrid A.M.van der VeldtclHarmen J.G.van de Werkenabm†Martijn P.J.Lolkemac†Joost L.Boormansbâ€
Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy
Peter-Paul M.WillemseaNiall F.DavisbcNikolaosGrivasdFabioZattonieMichaelLardasfErikBriersgMarcus G.CumberbatchhMariaDe SantisijPaoloDell'OgliokJames F.DonaldsonlmNicolaFossatikGiorgioGandagliakSilkeGillessennopJeremy P.GrummetqAnn M.HenryrMatthewLiewsStevenMacLennantMalcolm D.Masonu…Thomas B.L.Lamlm
Active Surveillance for Prostate Cancer: Will Magnetic Resonance Imaging Help Us Address the Current Controversies in Traditional Surveillance Approaches?
JohnWithingtonCaroline M.Moore
Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis
Thi OanhBuiabVan TuDaoabVan TaiNguyenabcJean-PaulFeugeasdeFrédéricPamoukdjianbfgGuilhemBousquetbcdf
Genomic Meta-analysis of Clear-cell Renal Cell Carcinoma (ccRCC): Aggregating Tumors to Resolve the Complexity of ccRCC
Kathryn H.GessneraWilliam Y.KimbIbardo A.Zambranoa
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial
ShankarSivaabMathiasBresselaSimon T.WoodcdMark G.ShawaShereneLoiabShahneen K.SandhuabBenTranabArunA. AzadabJeremy H.LewinaKatharine E.CuffcdHoward Y.LiucdDanielMoonaeJeremyGoadaLih-MingWongeMichaelLimJoonaJenniferMooiaSaratChanderaDeclan G.Murphyab…DavidPryorcf
Stereotactic Ablative Radiotherapy as a Tool in Renal Cell Carcinoma for Building RAPPORT with Systemic Therapy
CaroleMercierabMichielStrijboscPietOstad
To Transect or Not Transect: Results from the Scandinavian Urethroplasty Study, A Multicentre Randomised Study of Bulbar Urethroplasty Comparing Excision and Primary Anastomosis Versus Buccal Mucosal Grafting
Ole JacobNilsenabHenriette VeibyHolmaTeresa O.EkerhultcdKlasLindqvistcdBeataGrabowskaeBeataPerssoneJukkaSairanenf
Penile Complications After Urethroplasty: Who Cares?
SilkeRiechardt*
Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial
AbdullatifAydınaKamranAhmedabTakashigeAbecNicholasRaisonaMiekeVan HemelrijckdHansGarmodHashim U.AhmedefFurhanMukhtaraAhmedAl-JabiraOliverBrunckhorstaNobuoShinoharacWeiZhugGuohuaZenggJohn P.SfakianoshMantuGuptahAshutoshTewarihAli SerdarGözeniJensRassweileri…TrevorMarsh
Proficiency-based Progression Training: A Scientific Approach to Learning Surgical Skills
Anthony G.GallagherabcRubenDe GrooteabdMarcoPaciottiaefAlexandreMottriead
Description of Surgical Technique and Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1–2b Study)
AkshaySoodab†WoojuJeonga†IsaacPalma-ZamoraaFirasAbdollahabMohitButaneyaNicholasCorsiaHallieWurstaSohrabAroraaNaveenKachrooaOudaiHassancNileshGuptacMichael A.GorindeManiMenonabf
Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience
DeepikaReddyabMaxPeterscTaimur T.ShahabMariekevan SoncMariana BertoncelliTanakabPhilipp M.HuberdDerekLomaseArnasRakauskasfSaifulMiahgDavidEldred-EvansaStephanieGuillaumierhiFeargusHosking-JervisaRyanEngleaTimDudderidgejRichard G.HindleyklAmrEmarakxRajNigammnNeilMcCartanhi…Hashim U.Ahmedabvwâ€
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis
ZhenjieWua†QiChenb†LeQucMingminLidLinhuiWangaMaria C.MireUmbertoCarbonarafSavio D.PandolfogPeter C.BlackhAsit KPauliGiuseppeDi LorenzojkFrancescoPorpiglialAndreaMarimAndreaNecchinMorganRouprêtoSarah P.PsutkapRiccardoAutorinog
Re: Preoperative Intravenous Iron to Treat Anaemia Before Major Abdominal Surgery (PREVENTT): A Randomised, Double-blind, Controlled Trial
AndrewDeytrikhAidan P.Noon
Re: Dusting Efficiency of a Novel Pulsed Thulium:Yttrium Aluminum Garnet Laser vs a Thulium Fiber Laser
OlivierTraxerMarielaCorralesAlbaSierra del Rio
Re: Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study
AndreaGallioliAlbertoBredaJoanPalou
Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study
Divya A.ParikhabAli RazaKhakibStephen B.Williamsc
Re: Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study
ElisabethGrobet-JeandinabUgoPinaraMorganRouprêta
Re: Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
Rolf I.SkotheimabUlrikaAxcronaacKarolAxcronaad
Adjuvant Therapy After Surgical Resection of Nonmetastatic Renal Cell Carcinoma: One Size Does Not Fit All
Zine-EddineKheneaAxelBexbKarimBensalaha
A Point-of-Care Resource to Improve Care of Patients with Adrenal Mass: www.AdrenalMass.org
MarshallStrotheraJulieHallanger JohnsonbAlexanderKutikovc
Differential Impact of COVID-19 on Urological Surgeries in Public and Private Institutions at a Nationwide Level: Towards the Day of Reckoning
MathildeBrumentChristianPfisterJean-NicolasCornu
Restaging of Patients with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy Using [68Ga]-PSMA-11 Positron Emission Tomography/Computed Tomography: Impact on Disease Management
MathieuGauthéaPaulSargosbNicolasBenziane OuaritinibEricBarretcJean-BaptisteBeauvaldLaurentBrureaueGillesCréhangefCharlesDarianegGaëlleFiardhGaëlleFromontiRomainMathieujRaphaëleRenard-PennakGuilhemRoubaudlAlainRuffionmMorganRouprêtnGuillaumePloussarddoon behalf of the Cancerology Committee of the French Association of Urology
Re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316–7.: Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
Joep J.de JongaEwan A.Gibbb
Reply to Joep J. de Jong and Ewan A. Gibb’s Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316–7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
GottfridSjödahlabJohanAbrahamssonabKarinHolmstencdCarinaBernardoePontusErikssonePetterKollbergabNour-al-DainMarzoukaeMattiasHöglundeAndersUlléncfFredrikLiedbergab
Re: Trey Durdin, Alvin Goh, Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol 2021;80:16–7: Transurethral Resection of Bladder Tumor in Diagnosis of Muscle-invasive Bladder Cancer: Old-fashioned Endoscopic Surgery is Here to Stay
ElisabethGrobet-JeandinabUgoPinaraMorganRouprêta
Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274–82.
YeLeiYongZhangNianzengXing
Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274–82
GiulioFrancoliniaLucia P.CicconebLorenzoLiviab
Reply to Davide Rosati, Riccardo Lombardo, Cosimo De Nunzio, Constantino Leonardo, and Andrea Tubaro’s Words of Wisdom re: Transperineal Interstitial Laser Ablation of the Prostate, A Novel Option for Minimally Invasive Treatment of Benign Prostatic Obstruction. Eur Urol 2021;80:673–4
GaetanoDe RienzoaPaoloMinafrabPasqualeDitonnoa
